Publication at First Faculty of Medicine |
2014
Abstract
Everolimus is an oral kinase inhibitor of mammalian target of rapamycin (mTOR), a key component of many cellular signalling pathways. Everolimus has antiproliferative and antiangiogenic activity.
Currently, everolimus is a part of standard treatment algorithms for metastatic renal cell carcinoma (mRCC). It is indicated in the second and third-line therapy for mRCC.
Everolimus is relatively well tolerated and has demonstrated prolonged survival in patients progressing on vascular endothelial growth factor receptor (VEGFR) inhibitors, which is currently the largest class of agents indicated for mRCC.